First manufacturing suite expected to be in place by the end of 2015
Biopharmaceutical company Alvotech and California-based Finesse Solutions have entered into a partnership that will provide Alvotech with world-class, scalable, flexible and cost-efficient manufacturing and laboratory technology through the Finesse turnkey SmartFactory GMP manufacturing platform suite. SmartFactory is a single-use cGMP bio-manufacturing capacity that will allow Alvotech to rapidly expand its biosimilars business. Finesse’s customers will benefit from unprecedented access to Alvogen’s commercial, FDA-approved biomanufacturing facility.
\'This partnership allows us to leverage Finesse’s single-use biomanufacturing automation platform, combining best-of-breed bioprocess equipment from upstream through downstream,\' said Dr Andreas Herrmann, CEO of Alvotech. \'This strategic relationship provides us with much-needed additional manufacturing capacity and scale-up capabilities which will allow us to expedite our ambitions to become a global leader in the high-growth biopharmaceutical industry.
\'The first manufacturing suite will be in place by the end of 2015.\'
Dr Barbara Paldus, CEO of Finesse, added: \'Alvotech is capitalising on the extraordinary flexibility afforded by SmartFactory, and together we will be able to implement cutting-edge, innovative solutions for established and development-stage biosimilars processes.
\'The Alvotech facility will showcase our latest SMART technologies in process control, batch automation and data management. This partnership will also provide us with an important path to offer full-scale commercial manufacturing to our customers.\'